WANG Tao-tao1, SUN Jin-yue1, CHEN Si-yin1, CAI Jiang-xia1, CHENG Xiao-liang2, WANG Xue3, DONG Hai-yan1, DONG Ya-lin1*
1. Department of Pharmacy, The First Affiliated Hospital of Xi��an Jiaotong University, Xi��an 710061, China; 2. Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China; 3. Central Intensive Care Unit, The First Affiliated Hospital of Xi��an Jiaotong University, Xi��an 710061, China
Abstract��
OBJECTIVE To characterize the pharmacokinetics of voriconazole, find the factors influencing pharmacokinetics and optimize dosing regimen in patients with invasive fungus infections(IFIs). METHODS To prospectively quantitate the relationship between VRC parameters and covariates, a population pharmacokinetics analysis was conducted on pooled data from patients with invasive fungus infections. The list of covariates tested included demographic factors, biochemistry, concomitant medications and CYP2C19 genotype. The final model was internally evaluated using bootstrap method. Monte Carlo simulation was used to evaluate the effective of currently recommended dosing regimen and to design an optimized pharmacodynamics dosing strategy for VRC.RESULTS Four hundred and six samples from 151 patients were collected for population pharmacokinetics analysis. A one-compartment model with first-order absorption and elimination as the basic structural model appropriately fitted the data. VRC clearance was 6.95 L�h-1, volume of distribution was 200 L. The clearance was significantly association with age, alkaline phosphatase and CYP2C19 genotype. Bootstrap method confirmed that the pharmacokinetics parameters was accurate and the final model was robust. Monte Carlo simulation suggests that recommended dosing regimen for treat Aspegllius infections and 300 mg q12 h po or 200 mg q12 h iv.drip for treat Candida infections are effective.CONCLUSION This study is able to show that the optimal VRC dosage regimens are successfully determined using prospective population pharmacokinetics analysis and Monte Carlo simulation.
WANG Tao-Tao-,
SUN Jin-Yue-,
CHEN Si-Ying- etc
.Population Pharmacokinetics Study of Voriconazole and Dosing Regimen Optimization in Patients with Invasive Fungus Infections[J] Chinese Pharmaceutical Journal, 2014,V49(3): 227-133
��
[1]
THEURETZBACHER U, IHLE F, DERENDORF H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet, 2006, 45(7):649-663. COCCHI S, CODELUPPI M, VENTURELLI C, et al. Fusariumverticillioidesfungemia in a liver transplantation patient: Successful treatment with voriconazole. Diagn Microbiol Infect Dis, 2011, 71(4):438-441. CHEN K H, XIANG J Q, GUO X H, et al. Study on bioequivalence of voriconazole dispersible tablets in healthy volunteers. Chin Pharm J(�й�ҩѧ��־), 2007, (16):1241-1243. PIEPER S, KOLVE H, GUMBINGER H G, et al. Monitoring of voriconazole plasma concentrations in immunocompromisedpaediatric patients. J Antimicrob Chemother, 2012, 67(11):2717-2724. LEE S, KIM B, NAM W, et al. Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers. J Clin Pharmacol, 2012, 52(2):195-203. EIDEN C, COCIGLIO M, HILLAIRE-BUYS D, et al. Pharmacokinetic variability of voriconazole and N-oxide voriconazole measured as therapeutic drug monitoring. Xenobiotica, 2010, 40(10):701-706. BOYD A E, MODI S, HOWARD S J, et al. Adverse reactions to voriconazole. Clin Infect Dis, 2004, 39(8):1241-1244. PASCUAL A, CALANDRA T, BOLAY S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis, 2008, 46(2):201-211. RACIL Z, WINTEROVA J, KOUBA M, et al. Monitoring trough voriconazole plasma concentrations in haematological patients: Real life multicentre experience. Mycoses, 2012, 55(6):483-492. WEISS J, TEN HOEVEL M M, BURHENNE J, et al. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J Clin Pharmacol, 2009, 49(2):196-204. HAMADA Y, SETO Y, YAGO K, et al. Investigation and threshold of optimum blood concentration of voriconazole: A descriptive statistical meta-analysis. J Infect Chemother, 2012, 18(4):501-507. NAILOR M D, CHANDRASEKAR P H. Antifungal drugs: Predicting clinical efficacy with pharmacodynamics. Expert Rev Clin Pharmacol, 2009, 2(4):373-379. ANDES D, MARCHILLO K, STAMSTAD T, et al. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother, 2003, 47(10):3165-3169. SERENA C, GILGADO F, MARINE M, et al. Efficacy of voriconazole in a guinea pig model of invasive trichosporonosis. Antimicrob Agents Chemother, 2006, 50(6):2240-2243. SUN H K, KUTI J L, NICOLAU D P. Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: A report from the OPTAMA Program. Crit Care Med, 2005, 33(10):2222-2227. PASCUAL A, CSAJKA C, BUCLIN T, et al. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: Population pharmacokinetics-based analysis of adult patients with invasive fungal infections. Clin Infect Dis, 2012, 55(3):381-390. MOUTON J W, DUDLEY M N, CARS O, et al. Standardization of pharmacokinetic/pharmacodynamic(PK/PD) terminology for anti-infective drugs: An update. J Antimicrob Chemother, 2005, 55(5):601-607. MASTERTON R G, KUTI J L, TURNER P J, et al. The OPTAMA programme: Utilizing MYSTIC(2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe. J Antimicrob Chemother, 2005, 55(1):71-77. MIKUS G, SCHOLZ I, WEISS J. Pharmacogenomics of the triazole antifungal agent voriconazole. Pharmacogenomics, 2011, 12(6):861-872. KARLSSON M O, LUTSAR I, MILLIGAN P A. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob Agents Chemother, 2009, 53(3):935-944. TAN K, BRAYSHAW N, TOMASZEWSKI K, et al. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol, 2006, 46(2):235-243. LOMBARDI L R, MIANO T A, DAVIS J L, et al. A retrospective analysis of the effect of patient-specific factors on voriconazole concentrations in oncology patients. J Oncol Pharm Pract, 2012, 18(1):3-9. WAHLBY U, THOMSON A H, MILLIGAN P A, et al. Models for time-varying covariates in population pharmacokinetic-pharmacodynamic analysis. Br J Clin Pharmacol, 2004, 58(4):367-377. TRIFILIO S, ORTIZ R, PENNICK G, et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant, 2005, 35(5):509-513. MITSANI D, NGUYEN M H, SHIELDS R K, et al. Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: Factors impacting levels of and associations between serum troughs, efficacy, and toxicity. Antimicrob Agents Chemother, 2012, 56(5):2371-2377. KLOTZ U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev, 2009, 41(2):67-76. LAT A, THOMPSON G R. Update on the optimal use of voriconazole for invasive fungal infections. Infect Drug Resist, 2011, 4:43-53. LEVEQUE D, NIVOIX Y, JEHL F, et al. Clinical pharmacokinetics of voriconazole. Int J Antimicrob Agents, 2006, 27(4):274-284. SCHOLZ I, OBERWITTLER H, RIEDEL K D, et al. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol, 2009, 68(6):906-915. OSTROSKY-ZEICHNER L, REX J H, PAPPAS P G, et al. Antifungal susceptibility survey of 2, 000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother, 2003, 47(10):3149-3154.
2014, Vol. 49 
